Characterization of the serotonin transporter in lymphocytes and platelets of schizophrenia patients treated with atypical or typical antipsychotics compared to healthy individuals

European Neuropsychopharmacology

Volumn 16, Issue 6, 2006, Pages 429-436

  Barkan, Tal ^a   Peled, Avi ^b   Modai, Ilan ^b   Weizman, Abraham ^a   Rehavi, Moshe ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

Author keywords

Antipsychotics; Lymphocytes; Platelets; Schizophrenia; Serotonin; Serotonin transporter

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BIPERIDEN; CITALOPRAM; CLONAZEPAM; CLOTIAPINE; CLOZAPINE; DIAZEPAM; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LEVOMEPROMAZINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; OXAZEPAM; PERPHENAZINE; PROCYCLIDINE; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN TRANSPORTER; THIORIDAZINE; TOPIRAMATE; TRIHEXYPHENIDYL; TRITIUM; VALPROIC ACID; ZIPRASIDONE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE;

ADULT; ARTICLE; BINDING AFFINITY; CELL DENSITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOSE RESPONSE; DRUG BINDING SITE; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROPHARMACOLOGY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; SCHIZOPHRENIA; SEROTONIN UPTAKE; SEROTONINERGIC SYSTEM; THROMBOCYTE;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD PLATELETS; CITALOPRAM; FEMALE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; PROTEIN BINDING; SCHIZOPHRENIA; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 33745699119     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2005.11.008     Document Type: Article

References (48)

1. Addington D., Addington J., and Maticka-Tyndale E. Assessing depression in schizophrenia in the Calgary depression scale. Br. J. Psychiatry 164 (1993) 39-44
2. Andreasen N.C. Symptoms, signs and diagnosis of schizophrenia. Lancet 346 (1995) 477-481
3. Arora R.C., and Meltzer H.Y. Effects of chlorpromazine on serotonin uptake in blood platelets. Psychiatry Res. 9 (1983) 23-28
4. Arora R.C., and Meltzer H.Y. Serotonin2 receptor binding in blood platelets of schizophrenic patients. Psychiatry Res. 47 (1993) 111-119
5. Ashton H. Brain System Disorders and Psychotropic Drugs (1992), Blackwell, Oxford
6. Barkan T., Gurwitz D., Levy G., Weizman A., and Rehavi M. Biochemical and pharmacological characterization of the serotonin transporter in human peripheral blood lymphocytes. Eur. Neuropsychopharmacol. 14 (2004) 237-243
7. Breier A., Wolkowitz O.M., Doran A.R., Roy A., Boronow J., Hommer D.W., and Pickar D. Neuroleptic responsivity of negative and positive symptoms in schizophrenia. Am. J. Psychiatry 144 (1987) 1549-1555
8. 3H]Paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. J. Neurochem. 64 (1995) 1197-1202
9. Fernstrom J.D., and Wurtman R.J. Brain serotonin content: increase following ingestion of carbohydrate diet. Science 174 (1971) 1023-1025
10. Goff D.C., Midha K.K., Sarid-Segal O., Hubbard J.W., and Amico E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl) 117 (1995) 417-423
11. Golden R.N., and Gilmore J. Serotonin and mood disorder. Psychiatr. Ann. 20 (1990) 580-586
12. 2A receptors in schizophrenic patients with and without neuroleptic treatment. Psychiatry Res. 96 (2000) 41-50
13. Govitrapong P., Mukda S., Turakitwanakan W., Dumrongphol H., Chindaduangratn C., and Sanvarinda Y. Platelet serotonin transporter in schizophrenic patients with and without neuroleptic treatment. Neurochem. Int. 41 (2002) 209-216
14. 3H]-LSD. Effects of chronic neuroleptic and antidepressant drug administration. Experentia 44 (1988) 142-145
15. Hiemke C., Peled A., Jabarin M., Hadjez J., Weigmann H., Hartter S., Modai I., Ritsner M., and Silver H. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J. Clin. Psychopharmacol. 22 (2002) 502-506
16. Jacobs B.L. Serotonin and behavior: emphasis on motor control. J. Clin. Psychiatry 52 suppl 12 (1991) 17-23
17. Jockers-Scherubl M.C., Bauer A., Godemann F., Reischies F.M., Selig F., and Schlattmann P. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. Int. Clin. Psychopharmacol. 20 (2005) 27-31
18. Joyce J.N., Shane A., Lexow N., Winokur A., Casanova M.F., and Kleinman J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8 (1993) 315-336
19. Kane J., Honigfeld G., and Singer J. Clorazil collaborative study group. Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45 (1988) 789-796
20. Kay S.R., Fiszbein A., and Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
21. Laruelle M., Abi-Dargham A., Casanova M.F., Toti R., Weinberger D.R., and Kleinman J.E. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia: a postmortem study. Arch. Gen. Psychiatry 50 (1993) 810-818
22. Lauder J.M. Hormonal and humoral influences on brain development. Psychoeuroendocrinology 8 (1983) 121-155
23. Lauder J.M., and Krebs H. Serotonin as a differentiation signal in early neurogenesis. Dev. Neurosci. 1 (1978) 15-30
24. Lingjaerde O. Serotonin uptake and efflux in blood platelets from untreated and neuroleptic-treated schizophrenics. Biol. Psychiatry 18 (1983) 1345-1356
25. Linnoila M., Virkkunen M., and Scheinen M. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from non-impulsive violent behavior. Life Sci. 33 (1983) 2609-2614
26. Lowery O.H., Rosenbrough N.J., Farr A.L., and Randall R.J. Protein measurements with the folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
27. Marazziti D., Placidi G.F., Cassano G.B., and Akiskal H.S. Lack of specificity of reduced platelet imipramine binding in different psychiatric conditions. Psychiatry Res. 30 (1989) 21-29
28. Meltzer H.Y., Matsubara S., and Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin pKi values. J. Pharmacol. Exp. Ther. 251 (1989) 238-246
29. 2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J. Pharmacol. Exp. Ther. 265 (1993) 498-508
30. Meltzer H.Y., and Fatemi S.H. The role of serotonin in schizophrenia and the mechanism of action of antipsychotic drugs. Serotonergic mechanisms. In: Kane J.M., Moller H.J., and Awouters F. (Eds). Antipsychotic Treatment (1996), Marcel Dekker, New York 77-107
31. Modai I., Rotman A., Munitz H., Tyano S., and Wijsenbeek H. Serotonin uptake by blood platelets of acute schizophrenic patients. Psychopharmacology 64 (1979) 193-195
32. 3H]paroxetine. J. Neural Transm. 103 (1996) 749-757
33. Peuskens J., and Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br. J. Psychiatry 166 (1995) 712-726
34. Pickar D., Owen R.R., and Litman R.E. Clinical and biological response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch. Gen. Psychiatry 49 (1992) 345-353
35. Pincus H.A., First M., Frances A., and McQueen L. Reviewing DSM-IV. Am. J. Psychiatry 153 (1996) 850
36. 3H]Citalopram binding to brain and platelet membranes of human and rat. J. Neurochem. 56 (1991) 248-252
37. Rotman A., Shatz A., and Szekely G.A. Correlation between serotonin uptake and imipramine binding in schizophrenic patients. Prog. Neuro-psychopharmacol. Biol. Psychiatry 6 (1982) 57-61
38. Silver H., and Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia. An add-on double-blind, placebo-controlled study. Biol. Psychiatry 31 (1992) 698-704
39. Silver H., and Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia. J. Clin. Psychopharmacol. 18 (1998) 208-211
40. Silver H., Barash I., Aharon N., Kaplan A., and Poyurovsky M. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int. Clin. Psychopharmacol. 15 (2000) 257-261
41. Soubrie P. Reconciling the role of central serotonin neurons in human and animal behavior. Behav. Brain Res. 9 (1989) 319-364
42. Spina E., De Domenico P., Ruello C., Longobardo N., Gitto C., Ancione M., Di Rosa A.E., and Caputi A.P. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int. Clin. Psychopharmacol. 9 (1994) 281-285
43. Stahl S.M. Essential Psychopharmacology. 2nd Ed. (2000), Cambridge University Press, New York, NY
44. Stahl S.M. Describing an atypical antipsychotic: receptor binding and its role in pathophysiology. Primary care companion. J. Clin. Psychiatry 5 suppl 3 (2003) 9-13
45. Tarazi F.I., Zhang K., and Baldessarini R.J. Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain. Neurosci. Lett. 287 (2000) 81-84
46. Tollefson G.D., Beasley Jr. C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., Graffeo K.A., and Thieme M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry 154 (1997) 457-465
47. Warner R., and De Girolamo G. Clinical descriptions and diagnostic guidelines. In: Warner R., and De Girolamo G. (Eds). Schizophrenia (1995), World Health Organization, Geneva 111-118
48. 3H]imipramine binding in autism and schizophrenia. Psychopharmacology 91 (1987) 101-103